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Abstract
Objective: Major trauma is characterized by a pro-inflammatory response, followed by an immunosuppression. Recently, in
trauma patients, the lack of recovery of monocyte Human Leukocyte Antigen DR (mHLA-DR, a biomarker of ICU-acquired
immunosuppression) between days 1–2 and days 3–4 has been demonstrated to be independently associated with sepsis
development. The main objective of this study was to determine whether early measurements of IL-6 (interleukin-6) and IL-
10 plasma concentrations (as markers of initial severity) could improve, in association with mHLA-DR recovery, the
prediction of sepsis occurrence in severe trauma patients.
Design: Prospective observational study over 24 months in a Trauma ICU at university hospital.
Patients: Trauma patients with an ISS over 25 and age over 18 were included.
Measurements and Main Results: mHLA-DR was assessed by flow cytometry, IL-6 and IL-10 concentrations by ELISA. 100
consecutive severely injured patients were monitored (mean ISS 37610). 37 patients developed sepsis. IL-6 concentrations
and slope of mHLA-DR expression between days 1–2 and days 3–4 were significantly different between septic and non-
septic patients. IL-10 was not detectable in most patients. After adjustment for usual clinical confounders, when assessed as
a pair, multivariate logistic regression analysis revealed that a slope of mHLA-DR expression (days 3–4/days 1–2)#1.1 and a
IL-6 concentration $ 67.1 pg/ml remained highly associated with the development of sepsis (adjusted OR 18.4, 95% CI 4.9;
69.4, p=.00002).
Conclusions: After multivariate regression logistic analysis, when assessed as a pair, a high IL-6 concentration and a
persistent mHLA-DR decreased expression were found to be in relation with the development of sepsis with the best
predictive value. This study underlines the usefulness of daily monitoring of immune function to identify trauma patients at
a high risk of infection.
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Introduction
Severe injuries induce a systemic inflammatory response that
may be followed by an anti-inflammatory response [1], which
contributes to a state of transient immunosuppression [2,3,4]. The
latter is believed to be directly responsible for a detrimental
outcome in trauma patients and for lowering the resistance to
nosocomial infections in patients who have survived initial
resuscitation [5,6,7]. In the absence of specific clinical signs of
immune dysfunction in intensive care patients, biomarkers of
immunosuppression are clearly highly desirable. To date,
diminished expression of Human Leukocyte Antigen DR on
circulating monocytes (mHLA-DR) is widely accepted as a reliable
indicator of immunosuppression in Intensive Care Unit (ICU)
patients. Recently, a decreased in mHLA-DR expression has been
shown in severely injured trauma patients. Most importantly, it
appeared that the slope of mHLA-DR recovery was a significant
predictor of forthcoming sepsis [8]. Concerning the first
inflammatory step of trauma pathophysiology, a large number of
biomarkers has been studied, mainly with regard to severity.
Among them, Interleukin-6 (IL-6), which concentration is in
relation with the severity of injury [9,10,11], and IL-10, a major
component of the compensatory anti-inflammatory cascade [12],
have been demonstrated of interest. To our knowledge, no study
has been reported so far on concomitant assessment of those both
cytokines and mHLA-DR in severely injured trauma patients. As
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33095immunosuppression is hypothesized to be proportional to the
intensity of initial tremendous inflammation, we reasoned that
cumulative information from both initial cytokine response and
delayed evolution of mHLA-DR may provide improved informa-
tion regarding the risk of secondary infection development.
The main objective was thus to demonstrate in a cohort of
severe trauma patients that the combination of an early marker of
inflammation and mHLA-DR kinetics is a better predictor of
sepsis occurrence than each marker alone.
Materials and Methods
This work belongs to a global study on ICU-induced immune
dysfunctions. It has been approved by our Institutional Review
Board for ethics (‘‘Comite ´ de Protection des Personnes’’) which
waived the need for informed consent because biomarkers
expression was measured on residual blood after completing
routine follow-up. The study is registered at French Ministry of
Research and Teaching (#DC-2008-509) and is also recorded in
our commission for informatics and freedom (‘‘Commission
Nationale de l’Informatique et des Liberte ´s’’). As recommended,
patients or their family were orally informed of a samples
collection and of the purpose of the study.
This prospective observational study was carried out over a 24-
month period (July 2008 to June 2010). Management of trauma by
specialized physicians were guided with several protocols,
approved and followed by all the medical staff, and two medical
meeting took care in the ICU every day to discuss the evolution
and the treatment of patients. Inclusion criteria were an Injury
Severity Score (ISS) [13,14] of more than 25, admission to the
ICU and length of stay in ICU $ 3 days. Clinical exclusion
criteria were age of less than 18 years, ISS of less than 25,
aspiration pneumonia or gut perforation during the first hours
following trauma, chronic corticosteroid therapy, and death in the
first 48 hours after admission. Patients admitted on a Saturday
were excluded because mHLA-DR cannot be measured on day
1 or 2 (blood samples were not collected on Saturdays or Sundays,
when the laboratory did not operate).
All patients admitted were followed up prospectively until day
14 by daily clinical examination and biological tests. During
follow-up, clinical and biological data were collected. The data
collection comprised demographic characteristics (age and gen-
der), infection characteristics (source, microorganisms identified,
delay between trauma, and onset of sepsis), and outcome at 28
days (death or survival, with collection of the cause of death).
Therapeutic data were also collected (a) on admission to the
trauma room (the need for inotropic or vasoactive support and
blood products [packed red blood cells, fresh frozen plasma,
platelets concentrates, and albumin] and their quantities used to
sustain a mean arterial pressure [MAP] up to 70 mm Hg [or
90 mm Hg in the case of head injury], and the type and quantity
of prophylactic antibiotics) and (b) during support (number of
ventilator days, quantity and type of vasoactive support and of
blood products, and use of massive transfusion, which was defined
as more than 10 units of packed red blood cells [15,16] or the
replacement of the patient’s total blood volume [17] over a
24 hour period). Creatinine, lactate concentration, and abnormal
biphasic waveform (BPW) (MDAII analyzer, BioMe ´rieux, Marcy
L’Etoile, France) [18] were measured daily. Three clinical scores
were recorded: ISS on admission (range of 0 to 75), initial severity
of disease as assessed by the new Simplified Acute Physiology
Score II (SAPS II) (range of 0 to 164) [19] and the Sepsis-related
Organ Failure Assessment (SOFA) score (range of 0 to 24) on
admission and every day during follow-up [20]. Severe brain and
thoracic injuries, defined as an Abbreviated Injury Score (AIS) $
3, which are well established as risk factors for sepsis development,
were also taken into account [14].
This discovery cohort differed from 15% from that of our
previous study [8], as some patients were added (this study was
designed a year later) and other excluded due to absence of frozen
collected plasma.
The American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference definition of sepsis was used
for this study [21], namely the presence of an identifiable site of
infection and evidence of a SIRS on the basis of at least two of the
following criteria: (a) body temperature of greater than 38uCo ro f
less than 36uC, (b) heart rate of greater than 90 beats per minute,
(c) respiratory rate of greater than 20 breaths per minute or
hyperventilation as indicated by an arterial partial pressure of
carbon dioxide (PaCO2) of less than 32 mm Hg (less than 4.3 kPa),
and (d) a white blood cell count of greater than 12,000 cells/mm
3
or of less than 4,000 cells/mm
3 or the presence of more than 10%
immature neutrophils. The onset of sepsis was defined, as
recommended by the Consensus Conference [21], as the day on
which the site of infection was identified.
The final diagnosis of sepsis was retrospectively established by
two experts assessing the complete medical data, not involved in
case management and blind of the results. Diagnoses of
pneumonia and urinary infection were established according to
the guidelines of the American Thoracic Society and the Infectious
Diseases Society of America [22] and of the Centers for Disease
Control [23], respectively. Physicians were not informed of
mHLA-DR results. BPW was also determined as it may be used
as an indicator of sepsis development [24,25,26,27].
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood
samples were collected at 8 a.m. every 2 days after injury (on
Mondays, Wednesdays, and Fridays) (that is, at days 1–2, days 3–
4, days 5–6, days 7–8, days 9–10, and days 11–12). Data collected
on days 5–6, days 7–8, days 9–10, and days 11–12 are not
presented, as occurring after sepsis development. Flow cytometric
(FC500; Beckman Coulter, Hialeah, FL, USA) expression of
mHLA-DR was assessed on arterial, venous, or capillary blood.
Samplings were acquired through central venous or arterial
catheter, as the severity of the trauma required such equipments.
This avoided bias in the blood collection and platelet activation
associated with capillary blood sampling. Blood samples were
stored immediately at 4uC and stained within 2 hours after
collection, in accordance with the standardization recommenda-
tions for mHLA-DR measurement [28,29]. Staining and cell
acquisition were undertaken as described in the European
standardized protocol. Monoclonal antibodies and their respective
isotype controls were used according to the manufacturers’
recommendations: fluorescein isothiocyanate (FITC)-labeled anti-
CD14 (10 mL; Immunotech, Marseille France) and phycoerythrin
(PE)-labeled anti-HLA-DR (20 mL; BD Pharmingen, San Diego,
CA, USA) per 100 mL of whole blood. Monocytes were
characterized on the basis of their CD14 expression. Results were
expressed as the number of anti-HLA-DR antibodies per cell (AB/
C) (normal.15,000), which is correlated with the number of
HLA-DR molecules expressed on each monocyte [28]. Control
beads (Flowcheck, BeckmanCoulter) and stabilized blood (Im-
munotrol, BeckmanCoulter) were used on daily basis to check the
flow cytometer performance and to valid the accuracy. In
addition, calibration beads (QuantibriteH, Becton Dickinson) were
monthly run in order to provide results as AB/C. The remaining
plasma collected was separated in aliquot and frozen at -80uC.
As we decided to assess the early cytokine response induced by
trauma, the two first samples of each patient were analyzed (i.e.
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measured using commercial ELISA kits, according to the
manufacturers’ recommendations (Human IL-10 and IL-6 Duoset,
R&D Systems, Inc., Minnesota, United States). Recombinant
human IL-6 and IL-10 were used to produce a standard curve.
The detection limits were 7.8 pg/ml and 9.4 pg/ml respectively.
Every sample was analyzed in duplicate.
As sepsis, by itself, can modify mHLA-DR and interleukins
concentration, immunological data were censored and excluded
from the analysis once the onset of sepsis was established, thereby
precluding calculation of a difference in mHLA-DR expression
between septic and non-septic patients at days 7–8, 9–10, and 11–
12 (because of insufficient numbers of values for statistical
analysis). As a consequence, every patient who had a mHLA-
DR expression measured at days 3–4 did not present sepsis.
All data were verified for normality using the Kolmogorov-
Smirnov test. Baseline characteristics were described by frequency,
median and interquartile range (IQR) or, where appropriate,
mean 6 standard deviation. Patients were separated into two
groups, according to the development or not of sepsis. Groups
were compared using the Mann-Whitney U test for continuous
non-parametric variables, the independent paired t test for
continuous parametric variables and the chi-square test for
categorical data. Immunological values were stratified according
to the best threshold chosen using a Receiver operating
characteristic (ROC) curves analysis (i.e., maximized sensitivity
and specificity). ROC curves and the areas under the curve were
calculated for the slope in mHLA-DR between days 1–2 and days
3–4. mHLA-DR expression and IL-6 concentration were assessed
as a pair leading to four categories : mHLA-DR and IL-6 below
their respective optimal thresholds, one above and one below
(constituting two groups) and finally both above thresholds.
Univariate and different multivariate logistic regression analyses
were used to identify variables associated with the risk of infection
and assessed by odds ratios (OR) and 95% confidence intervals
(CI), using the different four groups constituted.
A 5% or lower p-value is considered to be statistically
significant. The Bonferroni correction was used to avoid spurious
results from the multiple statistical tests performed simultaneously.
The alpha value for three tests was .016. Medcalc software, version
9.6.4.0 (MedCalc, Mariakerke, Belgium) was used to perform the
statistical analyses.
Results
One hundred patients met the inclusion criteria between July
2008 and June 2010. Patients’ characteristics, therapeutic data and
immunological data are shown in Table 1 and Table 2. During
follow-up, no differences in renal function (assessed by plasma
creatinine concentration) or in lactate concentration were
observed (data not shown). Regarding the type of blood products
transfused, and prophylactic antibiotic, there were no differences
between groups (data not shown).
Five patients died (three from septic shock and two from
cardiogenic shock). No statistical test could be done on mortality
considering the poor number of patients.
Thirty-seven patients developed sepsis during follow-up, in a
mean delay of 5.162.4 days: pneumonia (n=31) and urinary tract
infection (n=6). Causative bacteria were fairly evenly distributed
between Gram-positive (n=14) and Gram-negative (n=22)
organisms. One patient had a mixed bacterial infection (Gram-
positive and -negative).
mHLA-DR expression and differences between septic and non-
septic patients are shown in Table 2 and Figure 1. As previously
described, ratios were calculated between values for two time
points. The slope of mHLA-DR expression (days 3–4/days 1–2)
showed a highly significant statistical difference between non-
septic and septic patients (Table 1). We next established a ROC
analysis (Figure 2). Area under curve for mHLA-DR slope (days 3–
4 /days 1–2) was .79 (p=.0001, IC95% .69; .88). The best
threshold to discriminate septic and non-septic patients (i.e., that
maximizes sensitivity and specificity) was 1.1 for mHLA-DR ratio.
At that threshold, the test had 82.6% sensitivity, 64.7% specificity,
51% Predictive Positive Value (PPV) and 89% Negative Predictive
Value (NPV).
At days 1–2, IL-6 concentration was significantly higher in
septic patients than in non-septic patients (Table 2, Figure 3). No
correlation was found between IL-6 concentration at days 1–2 or
3–4 and mHLA-DR expression (whatever days were considered),
severe brain (p=.3) or thoracic injury (p=.06).
The ROC curves analysis, with an area under curve at days 1–2
of .75 (p=.0001, IC95% .64; .84), provided a concentration $
67.1 pg/ml for IL-6 at days 1–2 as the best cut-off values to
discriminate septic and non-septic patients. At that threshold, the
test had 84.6% sensitivity, 72.5% specificity, 58% PPV and 90%
NPV (Figure 2). An IL-6 concentration $ 67.1 pg/ml at days 1–2
was highly associated with the development of sepsis and with the
need of vasoactive support during the two first days following
trauma (p,.0001). No correlation was found between mHLA-DR
expression (values or slope) and IL-6 concentration, whatever days
were considered.
IL-10 was rarely detectable in most trauma patients. Only 16
samples were above detection limit at days 1–2 (11 patients of
them developed sepsis, 3 patients died). Among them, 5 samples
were still positive at days 3–4, 11 became negative. As IL-10 was
present in a few samples, little statistics test could be done. The
presence of a detectable IL-10 at days 1–2 was associated with a
severe head injury (p=.03), mortality at days 28 (p=.01), and
shock at days 1–2 (p=.006), but not with sepsis development
(p=.3), massive transfusion (p=.36) nor major thoracic injury
(p=.19) (data not shown).
A control group of 18 healthy subjects (age and gender-
matched) was selected from among staff members of the intensive
care unit and employees working at the laboratory of immunology
(data not shown). None of these 18 subjects had detectable IL-6
nor IL-10.
The predictive capacities of clinical and immunological values
were tested in a univariate logistic regression analysis. We retained
parameters with p,.01. Mechanical ventilation has not been
taken into account as it is directly linked to head injury that is
included in the statistical model. Finally, only major head injury,
SAPS II and immunological values were included in the model
(Table 3). As IL-6 concentration and mHLA-DR expression were
not correlated, we could analyze them as a pair. Slope of mHLA-
DR expression between days 3–4 and days 1–2 and IL-6
concentration at days 1–2 were tested either independently (i.e.,
tested one by one with clinical variables) or in association as pair
(both above or under their best threshold) (Table 4). When
analyzed separately in the multivariate analysis, the two
immunological data provide an adjusted OR at 9.0 (IC95% 2.5;
32.8, p=.0009) or 10.9 (IC95% 3.0; 39.4, p=.0002).
Interestingly, when slope of mHLA-DR expression at days 3–4
and IL-6 concentration at days 1–2 were expressed as a pair (both
above their respective cut-off), after adjustment for other
confounding factors, they appeared as the best predictor for
developing sepsis, leading to an elevated adjusted OR at 18.4
(95% CI 4.9; 69.3, p=.00002) (Table 4). The characteristics of the
different immunologic statistical tests are presented in Table 5.
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Parameters
Overall population
n=100
Septic
n=37 (37%)
Non-Septic
n=63 (63%) p value
Age (years) 37617 35616 38617 .34 *
Male,% (n) 73% (n=73) 81% (n=30) 68% (n=43) .24
¤
ISS 37610 39683 5 610 .06 *
Severe brain injury,% (n) 38% (n=38) 57% (n=21) 27% (n=17) .006
¤
Severe thoracic injury,% (n) 74% (n=74) 62% (n=23) 81% (n=51) .07
¤
SAPS II 36.4615.4 42.5615.8 32.8614.1 .002 *
Need for vasoactive support in emergency room,% (n) 26% (n=26) 38% (n=14) 19% (n=12) .07
¤
Prophylactic antibiotics administrated in emergency room,% (n) 42% (n=42) 38% (n=14) 44% (n=28) .66
¤
SOFA score
D1 4 [2;7] 7 [4.25; 10] 3[2;5] ,.0001
{
D2 4 [2;6] 6[3.5; 10] 2.5 [1;5] ,.0001
{
D3 3 [2;6] 7 [3.5; 9] 2 [1;3] ,.0001
{
D4 3 [1;5] 5.5 [2.5; 8] 2 [1;3] ,.0001
{
D5 2 [1;4] 5 [1.5; 7.5] 1 [1;3] ,.0001
{
D6 1 [1;4] 4 [1.5; 7] 1 [1;2] ,.0001
{
Shock (need for vasoactive drug on D1–2),% (n) 35% (n=35) 59% (n=22) 21% (n=13) .0002
¤
Mechanical ventilation (MV),% (n) 66% (n=66) 89% (n=33) 52% (n=33) .0004
¤
Duration of MV, days 6 [3;12] 10 [6;19] 3 [2; 5.25] ,.0001
{
Massive transfusion required,% (n) 32% (n=32) 40% (n=15) 27% (n=17) .24
¤
Volume of global transfusion, ml 900 [0; 3,050] 1,800 [150; 4,300] 0 [0; 2,700] .02
{
Length of stay in ICU, days 9.5 [6;15] 15 [10.75; 24.25] 7 [5; 10.75] ,.0001
{
Non-survivors at day 28,% (n) 5% (n=5) 8% (n=3) 3% (n=2) .06
¤
Parametric variables are expressed as mean 6 standard deviation, and non-parametric variables as median (interquartile range) or frequencies.
*Independent samples t-test.
{Mann & Whitney test.
¤Chi-square test
Abbreviations: ISS, Injury Severity Score; SAPS, Simple Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; HLA, Human Leukocyte Antigen; ICU,
Intensive Care Unit; D, day; IL, Interleukin.
doi:10.1371/journal.pone.0033095.t001
Table 2. Immunological patients’ characteristics.
Parameters Overall population n=100 Septic n=37 (37%) Non-Septic n=63 (63%) p value
mHLA-DR levels, antibodies per cell
D1–2 11,40765,049 11,12065,341 11,97964,451 .48 *
D3–4 12,53667,508 9,64765,924 14,12067,848 .005 *
D5–6 15,42969,068 11,70766,004 16,43969,525 .06 *
Variations in mHLA-DR
D3–4/D1–2 1.276.56 .876.43 1.446.53 ,.0001 *
D5–6/D3–4 1.246.64 1.326.82 1.236.58 .62 *
IL-6 (pg/ml)
D1–2 63.2 [47.2; 114.9] 95.1 [71.3; 210.3] 55.7 [45.9; 83.8] .0004
{
D3–4 51.1 [44.9; 70.2] 67.2 [45.6; 186] 48 [42.7; 67.3] .01
{
IL-10 (pg/ml)
D1–2 , 7.8 [, 7.8; 7.8] , 7.8 [, 7.8; 7.8] , 7.8 [, 7.8; 7.8]
D3–4 , 7.8 [, 7.8; 7.8] , 7.8 [, 7.8; 7.8] , 7.8 [, 7.8; 7.8]
Parametric variables are expressed as mean 6 standard deviation, and non-parametric variables as median (interquartile range) or frequencies.
*Independent samples t-test.
{Mann & Whitney test.
Abbreviations: HLA, Human Leukocyte Antigen; D, day; IL, Interleukin.
doi:10.1371/journal.pone.0033095.t002
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Discussion
After initial resuscitation, the course of trauma patients is
characterized by an elevated risk of secondary sepsis responsible
for prolonged length of stay in ICU, extended duration under
mechanical ventilation and increasing morbidity. While recom-
mendations and guidelines are often provided regarding the initial
resuscitation, the second step of the disease has remained
somehow underinvestigated although it may offers new strategies
of prophylactic treatment against infection in the future [30].
Indeed, severe injury is now well known to be followed by a
relative immunosuppression with the alteration of a large number
of immune functions [31,32,33,34,35,36], which can become
harmful if it persists. These changes may increase susceptibility to
infection.
There are few markers of immune function in ICU. Of them, in
vitro LPS-induced TNF-a production and mHLA-DR expression
are the most frequently reported. However, mHLA-DR, being a
easily measurable surrogate marker of functional testing (compar-
ing to in vitro LPS-induced TNF-a production), has been widely
assessed in many ICU conditions [37]. To date, diminished
mHLA-DR expression has become the most reliable marker of
ICU-acquired immunosuppression [38]. Indeed, every stress
situation motivating the admission in ICU (i.e. surgical interven-
tions, sepsis, burns, stroke, trauma or pancreatitis) is characterized
by a state of immunosuppression, illustrated by an alteration of
mHLA-DR expression. While the potential of mHLA-DR
expression to predict outcome remains dependent of sampling
time (early measurements are not predictive in all conditions
[39,40,41,42,43]), it has been consensually demonstrated to be a
predictor of septic complications in various stress situations
[7,39,44,45,46]. In line, in a previous study, we reported that
the pattern of progression of mHLA-DR expression, i.e. the
recovery of mHLA-DR expression after days 1–2, was of interest
in predicting the development of sepsis after major trauma [8].
IL-6 is a pleiotropic cytokine, undetectable in healthy people,
Figure 1. Time course of mHLA-DR expression in trauma
patients, with (gray) or without (white bars) sepsis. mHLA-DR is
expressed as numbers of anti-HLA-DR antibodies bound per cell (AB/C).
Results are expressed as mean 6 standard deviation (t test, * p,.01).
mHLA-DR expression was not different between the two groups at days
1–2, but was significantly lower in septic patients than in non-septic
patients at days 3–4.
doi:10.1371/journal.pone.0033095.g001
Figure 2. ROC curve of mHLA-DR expression slope (dash line)
and IL-6 (full line) for predicting sepsis. Area under curves for
mHLA-DR slope (days 3–4 /days 1–2) and IL-6 at days 1–2 were
respectively .79 (95%CI .69; .88, p=.0001) and .75 (95%CI .64; .84,
p=.0001). The best threshold was 1.1 for mHLA-DR ratio (sensitivity
82.6%, specificity 64.7%) and 67.1 pg/ml for IL-6 concentration
(sensitivity 84.6% and specificity 72.5%).
doi:10.1371/journal.pone.0033095.g002
Figure 3. Time course of IL-6 concentration in trauma patients,
with (gray) or without (white bars) sepsis. Results (pg/ml) are
expressed as median [interquartile range] (Mann & Whitney U test,
*p ,.01). At days 1–2, IL-6 concentration was significantly higher in
septic patients than in non-septic patients, as at days 3–4 but with less
significance.
doi:10.1371/journal.pone.0033095.g003
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or undergoing a major surgery, an early elevation has been shown,
from the first to the 6
th hour. Its concentration was correlated with
development of septic complications or death [47,48,49,50]. In
trauma patients, the early elevation of IL-6 has been shown to be
related to the severity of trauma, the magnitude of the pro-
inflammatory response and complications (septic, multiple organ
failure, death) [50,51,52,53], even if no correlation has been found
in some other studies [54]. IL-10 is a major anti-inflammatory
mediator, undetectable in healthy people. It is elevated in septic
patients with a relation between its concentration, the severity of
sepsis and death [53,55,56]. The ratio IL-6/IL-10 concentration
has long been proposed to monitor the immunologic system of the
ICU-patient, as it reflects the pro and anti-inflammatory balance
(SIRS and CARS) [1,57]. A decrease of this ratio has been linked
to patients’ outcomes and development of sepsis after major
surgery [58,59]. In trauma patients, it seemed that there is a
relation between the level of IL-10 expression, the development of
sepsis and death [60]. To date and to the best of our knowledge,
no study has been reported so far where the concomitant
assessment of both cytokines together with mHLA-DR are proven
to be useful in the management of severely injured trauma
patients.
The descriptive data showed that severe thoracic injury was
more frequent in the non septic group. As revealed by univariate
logistic regression analysis, thoracic injury seemed protected from
sepsis (OR: 0.39). When data were analyzed individually, it
appears that patients who had isolated thoracic injury were more
often under non-invasive ventilation, when compared to those who
had a brain injury associated, who were more often under invasive
ventilation and who developed more infections.
In the present study, IL-10 was rarely above detection limit. A
relation between a detectable IL-10 and severe head injury has
been shown, in accordance with pathophysiological links between
brain injury, immunosuppression, and pneumonia development.
These results deserve to be further investigated in a severely brain
injured patients with ultra sensitive kits for IL-10 measurements.
In contrast, IL-6 levels were found to be elevated, with a median
concentration at days 1–2 of 63.2 pg/ml [47.2; 114.9], although it
was found below concentrations reported in several other works
[50,54,61]. As previously described [8,42], we observed a
moderate decrease in mHLA-DR expression. Collectively (mod-
erate IL-6 elevation and no detectable IL-10), these data suggest a
moderate activation of the inflammatory cascade followed by a
mild immunosuppression state induced by trauma. This may be
related to the improvement of patients’ resuscitation according to
the guidelines. This might also explain the fewer incidences of
sepsis and death observed when compared to other epidemiologic
studies [62,63].
Despite this moderate state of immunosuppression (low IL-6
concentration, relatively high mHLA-DR expression comparing to
shock septic patients and no detectable IL-10), we still observed a
difference between septic and non-septic patients regarding IL-6
concentration and mHLA-DR expression (values and slope of
expression). We may thus hypothesize that, after severe trauma,
patients who do not restore their mHLA-DR expression and
subsequently develop sepsis are those who presented the highest
IL-6 values at days 1–2. This association is not a proof of causative
relationship and deserves to be further investigated. However, it
appears that patients who developed infections are those who were
the furthest from the immunologic homeostasis.
As previously described [8], the predictive test (considering
sensibility and specificity) of the slope of mHLA-DR expression
provided good results, as confirmed by the multivariate analysis
(adjusted OR 9.0, 95%CI 2.5; 32.8, p=.0009). Similarly, early IL-
6 results were good independent predictors of sepsis occurrence
(adjusted OR 10.9, 95%CI 3.0; 39.4, p=.0002).
Most importantly, the major result of this study is that after
adjustment for usual clinical confounders (i.e. the presence of a
severe head injury and an elevated SAPS II), the combinative test
Table 3. Univariate logistic regression analysis according to
the biologic test used to predict sepsis development.
Univariate (n=100)
OR 95%CI p value
Severe head injury Positive 3.5 1.5 ; 8.4 .004
Severe thoracic injury Positive .4 .1 ; .96 .04
Massive transfusion Positive 1.8 .8 ; 4.4 .16
ISS $40 2.5 1.1 ; 5.9 .04
SAPS II $37 3.1 1.3 ; 7.1 .009
D3–4/D1–2 mHLA-DR #1.1 8.7 2.6 ; 29.5 .0005
D1–2 IL-6 $67.1 12.0 3.6 ; 40.7 .00006
D3–4/D1–2 mHLA-DR#1.1 &
D1–2 IL-6$67.1
Positive 21.0 5.8 ; 75.7 .000003
D3–4/D1–2 mHLA-DR.1.1 &
D1–2 IL-6$67.1
Positive .6 .1 ; 2.5 .49
D3–4/D1–2 mHLA-DR#1.1 &
D1–2 IL-6,67.1
Positive .4 .1 ; 1.7 .24
D3–4/D1–2 mHLA-DR.1.1 &
D1–2 IL-6,67.1
Positive .05 .007 ; .4 .006
CI, confidence interval; D, days; IL, Interleukin; ISS, Injury Severity Score; mHLA-
DR, monocyte human leukocyte antigen-DR; OR, odds ratio; SAPS II, Simple
Acute Physiology Score II.
doi:10.1371/journal.pone.0033095.t003
Table 4. Different multivariate logistic regression analysis
according to the biologic test used to predict sepsis
development.
Multivariate (n=77)
OR 95%CI
p
value
Severe head injury Positive 3.3 1.0 ; 11.0 .05
SAPS II $37 2.6 .8 ; 8.4 .1
D3–4/D1–2 mHLA-DR #1.1 9.0 2.5 ; 32.8 .0009
Severe head injury Positive 3.5 1.1 ; 11.6 .04
SAPS II $37 2.7 .8 ; 8.6 .1
D1–2 IL-6 $67.1 10.9 3.0 ; 39.4 .0002
Severe head injury Positive 2.7 .7 ; 9.9 .14
SAPS II $37 2.0 .5 ; 7.3 .3
D3–4/D1–2 mHLA-DR#1.1 & D1–2 IL-
6$67.1
Positive 18.4 4.9 ; 69.3 .00002
Severe head injury Positive 3.6 1.1 ; 12.1 .03
SAPS II $37 2.7 .8 ; 8.7 .09
D3–4/D1–2 mHLA-DR.1.1 & D1–2 IL-
6,67.1
Positive .05 .006 ; .4 .006
CI, confidence interval; D, days; IL, Interleukin; ISS, Injury Severity Score; mHLA-
DR, monocyte human leukocyte antigen-DR; OR, odds ratio; SAPS II, Simple
Acute Physiology Score II.
doi:10.1371/journal.pone.0033095.t004
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and days 1–2 and early IL-6 concentration at days 1–2 was found
to be independently associated with the risk of developing sepsis
with a significant elevated OR (adjusted OR 18.4, 95%CI 4.9;
69.3, p=.00002). When comparing the statistical characteristics of
the tests (Table 5), even if sensibility decreased, the specificity and
the PPV sharply increased when combining both markers thus
creating a better screening test. Moreover, in multivariate analysis,
this association was more predictive than each biomarker by itself,
doubling the adjusted OR. As the mean delay of sepsis was
5.162.4 days and as the data were censored from the statistical
analysis after sepsis occurrence, we assumed that this created a
predictive test for sepsis in trauma patients.
In the present study, we reasoned that cumulative information
from both initial cytokine response and delayed evolution of
mHLA-DR may provide improved information regarding the risk
of secondary infection development. Indeed, the association of
these two markers partially reflects the immunologic balance. The
early hyper-inflammatory response following trauma is character-
ized by a massive pro-inflammatory mediator release, such as IL-6,
which concomitantly induces the production of major anti-
inflammatory mediators such as IL-10 and down regulation of
mHLA-DR. This reflects a protective mechanism in order to
prevent tissue damage induced by uncontrolled inflammation.
Thus, as SIRS and CARS are connected, it is likely that the
magnitude of the first one is related to the magnitude of the second
one [33]. In line, it has been shown in previous studies that the
more far the patients were from the immunologic homeostasis
(activation or depression), the more they developed infections [64].
This may explain the relevance of the present results.
There are some limitations that need to be acknowledged and
addressed regarding the present study. The first limitation is that
this study is monocentric and only includes one hundred patients.
However it is important to note that such number of inclusions
remains high when compared to previous studies. Moreover our
cohort was homogenous regarding severity. Even if IL-6
concentration is quite low when compared to previous studies,
variations between groups were still found statistically significant.
In a previous study in which severe immunosuppression was
assessed by low mHLA-DR expression (around 30%), IL-10
measured with an automatic method was also barely detectable
[44]. Another limitation concerns the sequence sampling (i.e. every
2 days in the study design). Considering the mean delay of sepsis
(5.1 days), one next challenge is to evaluate whether a shortened
monitoring in the first 2 days could provide similar predictive
information regarding the risk of sepsis. If so, it would increase the
time window to develop strategies to control secondary sepsis.
Lastly, one limitation refers to the subgroup of patients with head
injury. As previously discussed, it is well known that they are at
higher risk of sepsis, as shown in Table 1. One would assume the
fact that this could represent a bias in our analysis. Nevertheless,
by conducting a multivariate analysis, the results were adjusted
with confounding parameters, including head injury.
In conclusion, to the best of our knowledge, this is the first study
to provide such a high OR to predict the risk of forthcoming sepsis
on the basis of biomarkers in trauma patients. Our results highlight
the interest to concomitantly assess early value of IL-6 concentra-
tion (as a marker for severity) and daily variation of mHLA-DR
expression (as a marker for persisting immunosuppression). Thus,
a panel of markers could be an innovative approach to follow
rapid changes in immune functions after injury. It would permit to
identify patients at a high risk of infection. To ‘‘pre-empt’’ the
development of sepsis, these patients could receive prophylactic
treatments, such as antibiotics [65], immunostimulant therapies
using interferon-gamma [66] or granulocyte-macrophage colony-
stimulating factor, as proposed in septic shock [31].
Conclusions
In conclusion, trauma induces a temporary, relative immuno-
suppression. In this preliminary study, the association between a
lack of mHLA-DR recovery and IL-6 concentration at days 1–2
can result in a performance test to predict sepsis. Multicentre
studies will have to be designed in order to confirm these
promising results in an independent population. Studies should
also focus on patients with major head injury and the
pathophysiological links with pneumonia development. This study
confirms the importance of inflammatory and immunologic
monitoring in trauma patients and the pivotal role of immune
dysfunction in the increased risk of infection in trauma patients.
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